A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132)

  • End date
    Jan 13, 2025
  • participants needed
  • sponsor
    Bausch Health Americas, Inc.
Updated on 13 October 2022
screening procedures
mini-mental status exam


Study RNLC3132 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in advanced liver cirrhosis, defined by the presence of medically controlled ascites.

Condition Hepatic Encephalopathy
Treatment Placebo, Rifaximin SSD
Clinical Study IdentifierNCT05297448
SponsorBausch Health Americas, Inc.
Last Modified on13 October 2022


Yes No Not Sure

Inclusion Criteria

Diagnosis of advanced liver cirrhosis with medically controlled ascites (>30 days) not requiring therapeutic paracentesis (prophylactic variceal banding allowed if no history of previous variceal bleeding)
Conn (West Haven Criteria) score of < 2\
Mini-Mental State Examination (MMSE) score > 24 at screening and baseline
≥ 18 and ≤ 85 years of age

Exclusion Criteria

Active COVID-19, history of SBP, EVP or AKI-HRS
History of OHE episode (Conn score ≥ 2)
Use, among others, non-study rifaximin, lactulose/lactitol (with exception of prior occasional, intermittent use of lactulose for non-OHE indications), benzodiazepine, and chronic antibiotics
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note